Actelion Hits Record on $18.9 Billion Shire Approach Report

Updated on

Actelion Ltd., the Swiss maker of treatments for a rare lung disease, rose to a record after the Sunday Times reported it received an informal approach from Shire Plc in recent weeks.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.